Rebate Reduction Requests underSections 11101 and 11102 of the Inflation Reduction Act (CMS-10858) - IRA
Revision of a currently approved collection
No
Regular
11/17/2026
table that charts list comparision
Requested
Previously Approved
36 Months From Approved
07/31/2027
20
20
6,200
620
0
0
The Centers for Medicare & Medicaid Services (CMS) is requesting review and approval of data collection related to section 11101 and 11102 of the Inflation Reduction Act of 2022 (IRA; P.L. 117-169). Under the authority in sections 11101 and 11102 of the IRA, CMS is implementing the Medicare Part B Drug Inflation Rebate Program and the Medicare Part D Drug Inflation Rebate Program codified in section 1847A(i) and section 1860D-14B of the Social Security Act (âthe Actâ), respectively. The statute provides that CMS must reduce or waive the rebate amount for a Part B biosimilar biological product and generic Part D rebatable drug or biosimilar when CMS determines there is a severe supply chain disruption, such as a disruption caused by a natural disaster or other unique or unexpected event. CMS also must reduce or waive the rebate amount for a generic Part D rebatable drug if CMS determines that without such reduction or waiver, the drug is likely to be described as in shortage during a subsequent applicable period. Some of the information and supporting documentation needed for CMS to make a determination regarding a severe supply chain disruption and the likelihood of a future shortage are held by manufacturers and are not available to CMS. For CMS to determine whether there is a severe supply chain disruption or likelihood of future shortage, in accordance with sections 1847A(i)(3)(G)(ii), 1860D-14B(b)(1)(C)(ii), and 1860D-14B(b)(1)(C)(iii) of the Act, a manufacturer must submit a request and supporting documentation (as described in Appendix A, B, C, and D, as applicable) to CMS to receive consideration for a rebate reduction.
CMS includes technical revisions to the Rebate Reduction Requests ICR Forms that are listed in the accompanying crosswalk of changes between the currently approved package and this proposed package. These revisions do not impact the burden. Although, burden has increased due to a more accurate calculation of the respondents and hours to develop and submit the forms.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.